Intellia Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NTLA and other ETFs, options, and stocks.

About NTLA

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. 

CEO
John M. Leonard
CEOJohn M. Leonard
Employees
403
Employees403
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2014
Founded2014
Employees
403
Employees403

NTLA Key Statistics

Market cap
2.25B
Market cap2.25B
Price-Earnings ratio
-4.38
Price-Earnings ratio-4.38
Dividend yield
Dividend yield
Average volume
6.12M
Average volume6.12M
High today
$20.85
High today$20.85
Low today
$19.89
Low today$19.89
Open price
$20.63
Open price$20.63
Volume
2.80M
Volume2.80M
52 Week high
$21.49
52 Week high$21.49
52 Week low
$5.90
52 Week low$5.90

NTLA News

TipRanks 1d
Intellia upgraded to Outperform from Market Perform at Citizens JMP

Citizens JMP analyst Silvan Tuerkcan upgraded Intellia Therapeutics (NTLA) to Outperform from Market Perform with a $33 price target The firm’s survey of North...

Simply Wall St 3d
Intellia Therapeutics Is Up 22.4% After Promising Phase 1 Data and ARK Investment Buy-In—What's Changed

Intellia Therapeutics recently announced results from its ongoing Phase 1 study, showing deep and lasting serum TTR reductions with evidence of clinical improve...

Intellia Therapeutics Is Up 22.4% After Promising Phase 1 Data and ARK Investment Buy-In—What's Changed
TipRanks 3d
CoreWeave, NuScale, Southern Co, Intellia, and Prospect Capital: Insider Moves Unveiled!

Insiders have been trading these 5 stocks: ((CRWV)), ((SMR)), ((SO)), ((NTLA)) and ((PSEC)). Here is a breakdown of their recent trades and their value. Elevate...

Analyst ratings

81%

of 26 ratings
Buy
80.8%
Hold
15.4%
Sell
3.8%

More NTLA News

TipRanks 4d
Intellia Therapeutics Executive Makes Notable Stock Sale

New insider activity at Intellia Therapeutics ( (NTLA) ) has taken place on October 3, 2025. Elevate Your Investing Strategy: Take advantage of TipRanks Premi...

Simply Wall St 4d
Intellia Therapeutics: Revisiting Valuation After Positive Clinical Advances and Pipeline Milestones

Interest in Intellia Therapeutics (NTLA) has been picking up following fresh long-term data for its lead gene-editing program, nexiguran ziclumeran, as well as...

Intellia Therapeutics: Revisiting Valuation After Positive Clinical Advances and Pipeline Milestones
TipRanks 7d
Cathie Wood’s ARK Investment buys 99K shares of Intellia Therapeutics today

20:32 EDT Cathie Wood’s ARK Investment buys 99K shares of Intellia Therapeutics (NTLA) today Published first on TheFly – the ultimate source for real-time, mar...

People also own

Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.